Anna Kent, DO
Hospice and Palliative Medicine · Mc Connellsburg, PANPI 1104189612
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,593, 9.7 times the $164 reported in 2023. Among hospice and palliative medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 185 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$567
- AstraZeneca$534
- Pfizer$346
- Lilly USA, LLC$282
- AbbVie$196
- GSK$176
- plus $891 from 19 others
What the payments were for
- Food & beverage$2,992100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 38 | $567 |
| AstraZeneca | 24 | $534 |
| Pfizer | 25 | $346 |
| Lilly USA, LLC | 26 | $282 |
| AbbVie | 10 | $196 |
| GSK | 13 | $176 |
| Otsuka America Pharmaceutical, Inc. | 6 | $110 |
| Phathom Pharmaceuticals, Inc. | 7 | $82 |
| Novartis | 4 | $77 |
| Sumitomo Pharma America, Inc. | 3 | $70 |
| E.r. Squibb & Sons, L.L.C. | 4 | $68 |
| Cequr Corporation | 1 | $63 |
| Astellas Pharma US Inc | 3 | $52 |
| Bayer | 3 | $51 |
| Boehringer Ingelheim | 3 | $47 |
| Exact Sciences | 2 | $45 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Amgen | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Averitas Pharma Inc. | 1 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Merck | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,992 in reported general payments places this provider in the 95th percentile of 73 hospice and palliative medicine providers in Pennsylvania.
See all hospice and palliative medicine providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 72 | $81,162 |
| EliquisApixaban | 84 | $65,463 |
| MounjaroTirzepatide | 46 | $57,119 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $46,691 |
| TrulicityDulaglutide | 32 | $29,560 |
| JardianceEmpagliflozin | 30 | $23,031 |
| XareltoRivaroxaban | 36 | $19,673 |
| LinzessLinaclotide | 14 | $15,720 |
| JanuviaSitagliptin Phosphate | 16 | $14,145 |
| FarxigaDapagliflozin Propanediol | 23 | $13,584 |
| MyrbetriqMirabegron | 19 | $11,995 |
| CreonLipase/Protease/Amylase | 20 | $11,692 |
| RybelsusSemaglutide | 11 | $9,379 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $4,315 |
| Fentanyl | 17 | $3,289 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $567 | $90,54183 claims |
| Lilly USA, LLCMounjaro, Trulicity | $282 | $86,67978 claims |
| PfizerEliquis | $346 | $65,46384 claims |
| GSKTrelegy Ellipta | $176 | $46,69172 claims |
| AbbVieLinzess, Creon | $196 | $27,41134 claims |
| Boehringer IngelheimJardiance | $47 | $23,03130 claims |
| MerckJanuvia | $15 | $14,14516 claims |
| AstraZenecaFarxiga | $534 | $13,58423 claims |
| Astellas Pharma US IncMyrbetriq | $52 | $11,99519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 73 hospice and palliative medicine providers in Pennsylvania.
Other hospice and palliative medicine in Mc Connellsburg
- Rupinder GillYork$10K
- Thomas DegregoryGreensburg$4K
- Chitra MohanChambersburg$3K
- Patrick RiceAltoona$3K
- Kathy SelvaggiButler$2K
- Vijayashree MokashiAllentown$2K
- John LiantonioPhiladelphia$795
- Erin KellyPhiladelphia$750
- Lauren SiglerMonroeville$707
- Fredric PricePittsburgh$628
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.